• Request for Information (RFI): Nomination of Molecular Targets Substantially Relevant to the Growth or Progression of Pediatric Cancers  
(NOT-CA-18-062) National Cancer Institute

• National Cancer Institute (NCI) Request for Information (RFI): Strategies for Matching Patients to Clinical Trial  
(NOT-CA-18-063) National Cancer Institute

• NCI Participation in PAR-18-694, Interdisciplinary Research Teams to Investigate Reciprocal Basic Behavioral and Social Linkages Between Sleep and Stress (R24 - Clinical Trial Optional)  
(NOT-CA-18-066) National Cancer Institute

• NCI Participation in PAR-18-733, Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03 - Clinical Trial Not Allowed)  
(NOT-CA-18-067) National Cancer Institute

• NCI Participation in PA-18-141, Mechanisms, Models, Measurement, & Management in Pain Research (R01 ClinicalTrial Optional)  
(NOT-CA-18-068) National Cancer Institute

• NCI Announcement of Interest in Supporting Immuno-Oncology Research and Career Development through NIH Parent PA-18-591, "Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)"  
(NOT-CA-18-056) National Cancer Institute

• NCI Request for Information (RFI): Input on Development of the NCI Imaging Data Commons  
(NOT-CA-18-060) National Cancer Institute

• Notice of NCI's participation on PAR-18-064, Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)  
(NOT-CA-18-061) National Cancer Institute

• Notice of Correction to Award Information in PAR-18-246 Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional)"  
(NOT-CA-18-064) National Cancer Institute

• Notice of Correction to Award Information in PAR-18-247 Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21 Clinical Trial Optional)"  
(NOT-CA-18-065) National Cancer Institute

• Notice of Change in Eligible Organizations in PA-18-748 Research Supplements to Promote Data Sharing in Cancer Epidemiology Studies (Admin Supp Clinical Trial Not Allowed)" to Allow Foreign Institutions.  
(NOT-CA-18-069) National Cancer Institute

• Presolicitation Notice: Request for Proposals (RFP) N01CN77019-18 "PREVENT Cancer Preclinical Drug Development Program: Preclinical Services for Biopharmaceutical Product Development and Manufacturing, Toxicology and Pharmacology Testing"  
(NOT-CA-18-070) National Cancer Institute

REQUEST FOR APPLICATIONS

• TITLE: Revision Applications to National Cancer Institute (NCI) Supported R01 Awards to Include Research on the NCIs Provocative Questions (R01 Clinical Trial Optional)  
(RFA-CA-18-021)  

SPONSOR: National Cancer Institute  

Synopsis: This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI R01 research grants. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-18-019 (R01) and RFA-CA-18-020 (R21). This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent R01 award.  
Application Receipt Date(s): June 29, 2018, October 30, 2018.
TITLE: Revision Applications to National Cancer Institute (NCI) supported U01 Awards to Include Research on the NCIs Provocative Questions (U01 Clinical Trial Optional)  
(RFA-CA-18-022)

SPONSOR: National Cancer Institute

Synopsis: This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI U01 research grants. These revision applications are expected to focus on research related to one of the 12 of the NCI’s Provocative Questions (PQs) published for new applications in RFA-CA-18-019 (R01) and RFA-CA-18-020 (R21). This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent U01 award.

Application Receipt Date(s): June 29, 2018, October 30, 2018.

TITLE: Improving the Reach and Quality of Cancer Care in Rural Populations (R01 Clinical Trial Required)  
(RFA-CA-18-026)

SPONSOR: National Cancer Institute

Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to reduce the burden of cancer and improve the quality of cancer care in rural areas among low-income and/or underserved populations. The FOA encourages two types of applications: 1) observational research that includes pilot testing of intervention to understand and address predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations, or 2) intervention research to address known predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations. Specifically, the focus for observational studies (with pilot testing) is understanding and addressing the predictive and/or mediating role of social determinants of health, barriers to care, and treatment; and the focus for interventional research is on addressing quality of care related to cancer diagnosis, treatment and/or survivorship.

Application Receipt Date(s): September 19, 2018

PROGRAM ANNOUNCEMENTS

TITLE: Research Supplements to Promote Data Sharing in Cancer Epidemiology Studies (Admin Supp Clinical Trial Not Allowed)  
(PA-18-748)

SPONSOR: National Cancer Institute

Synopsis: The purpose of the administrative supplement is to provide support for NIH-funded investigators to prepare and deposit individual-level data from cancer epidemiology studies into NIH/NCI-supported, controlled-access databases including the Cancer Epidemiology Data Repository (CEDR) and the database of Genotypes and Phenotypes (dbGaP). Sharing of research data will accelerate scientific discovery and increase opportunities for collaboration to provide new clues to cancer etiology, determine risk factors, and improve cancer survivorship.

Application Receipt/Submission Date(s): July 1, 2018

TITLE: Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN)(Admin Supp Clinical Trial Not Allowed)  
(PAR-18-752)

SPONSOR: National Cancer Institute

Synopsis: This administrative supplement funding opportunity announcement (FOA) from the National Cancer Institute (NCI) is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on exceptional scientific opportunities that could be accelerated through this initiative. As part of the Cancer Moonshot initiative, the NCI created the Drug Resistance and Sensitivity Network (DRSN), a collaborative network of centers of excellence (supported by U54 cooperative agreement awards) focused on using advanced techniques and models to accelerate understanding of issues of cancer resistance or extreme sensitivity to anticancer agents.

Application Receipt/Submission Date(s): June 30, 2018

TITLE: Harnessing Big Data to Halt HIV (R01 Clinical Trial Optional)  
(PAR-18-764)

SPONSOR: National Cancer Institute

Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to promote research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the
development of this scientific area is guided by ethical principles. Application Receipt/Submission Date(s): Standard dates apply

- **TITLE**: Translational Research on Adducts in Cancer Risk Identification and Prevention (U01) (PAR-18-703)
  **SPONSOR**: National Cancer Institute
  United States Department of Health and Human Services (HHS)
  **Synopsis**: This Funding Opportunity Announcement (FOA) encourages clinically-relevant translational/epidemiological research projects focused on the use of adducts to cellular macromolecules, as indicators of exposures to cancer risk factors in human populations and subgroups. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The projects are expected to be based on comprehensive use of human biospecimens for which detailed medical data are available (e.g., biospecimens from the NCI-supported cohort studies). The main emphasis of this FOA is on advancing the area of cancer detection, cancer prevention, and assessing cancer risks in human populations and subgroups. Nonetheless, studies evaluating the potential roles of adducts in cancer etiology for gene-environment interaction research may also be appropriate provided that such projects are based on appropriate sets of human biospecimens (such as specimens from cohorts studies supported by NIH).
  Application Receipt/Submission Date(s): July 11, 2018

- **TITLE**: Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01 Clinical Trial Optional). (PAR-18-703)
  **SPONSOR**: National Cancer Institute
  National Institute on Aging
  National Institute of Dental and Craniofacial Research
  National Institute of Nursing Research
  **Synopsis**: This Funding Opportunity Announcement (FOA) encourages research projects focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. These projects should explore the basic aspects of adducts/adductomics that may have a potential utility in cancer detection, cancer prevention, and/or assessing cancer risks.
  Application Receipt/Submission Date(s): Standard dates apply.

**OTHER FUNDING OPPORTUNITIES**
(Sponsors in bold are NIH Peer Reviewed Organizations)

- **TITLE**: Young Investigators Grants
  [http://breastcanceralliance.org/grants](http://breastcanceralliance.org/grants)
  **SPONSOR**: Breast Cancer Alliance (BCA)

- **TITLE**: Emerging Leader Awards
  [https://themarkfoundation.org/grants/?ct=t(EMAIL_CAMPAIGN_4_13_2018)](https://themarkfoundation.org/grants/?ct=t(EMAIL_CAMPAIGN_4_13_2018))
  **SPONSOR**: The Mark Foundation for Cancer Research

- **TITLE**: DoD Ovarian Cancer Pilot Award
  [https://www.grants.gov/custom/viewOppDetails.jsp?oppId=302975](https://www.grants.gov/custom/viewOppDetails.jsp?oppId=302975)
  **SPONSOR**: United States Department of Defense (DOD)

- **TITLE**: SWOG Early Exploration and Development (SEED) Fund
  **SPONSOR**: The Hope Foundation